High-Risk neuroblastoma (NB) survival rate is still <50%, despite treatments being more and more aggressive. The biggest hurdle liable to cancer therapy failure is the drug resistance by tumor cells that is likely due to the intra-tumor heterogeneity (ITH). To investigate the link between ITH and therapy resistance in NB, we performed a single cell RNA sequencing (scRNAseq) of etoposide and cisplatin resistant NB and their parental cells. Our analysis showed a clear separation of resistant and parental cells for both conditions by identifying 8 distinct tumor clusters in etoposide-resistant/parental and 7 in cisplatin-resistant/parental cells. We discovered that drug resistance can affect NB cell identities; highlighting the bi-directional ability of adrenergic-to-mesenchymal transition of NB cells. The biological processes driving the identified resistant cell subpopulations revealed genes such as (BARD1, BRCA1, PARP1, HISTH1 axis, members of RPL family), suggesting a potential drug resistance due to the acquisition of DNA repair mechanisms and to the modification of the drug targets. Deconvolution analysis of bulk RNAseq data from 498 tumors with cell subpopulation signatures showed that the transcriptional heterogeneity of our cellular models reflected the ITH of NB tumors and allowed the identification of clusters associated with worse/better survival. Our study demonstrates the distinct cell populations characterized by genes involved in different biological processes can have a role in NB drug treatment failure. These findings evidence the importance of ITH in NB drug resistance studies and the chance that scRNA-seq analysis offers in the identification of genes and pathways liable for drug resistance.

CEINGE Biotecnologie Avanzate Napoli 80145 Italy

Department of Chemistry and Biochemistry Mendel University in Brno Brno 61300 Czech Republic

Dipartimento di Ingegneria Chimica dei Materiali e della Produzione Industriale Università degli Studi di Napoli Federico 2 Napoli 80125 Italy

Dipartimento di Medicina Molecolare e Biotecnologie Mediche Università degli Studi di Napoli Federico 2 Napoli 80131 Italy

Dipartimento di Medicina Sperimentale Università di Genova 16132 Genova Italy

See more in PubMed

Maris J.M. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–2211. PubMed PMC

Capasso M., Diskin S.J. Genetics and genomics of neuroblastoma. Cancer Treat Res. 2010;155:65–84. PubMed

Depuydt P., Boeva V., Hocking T.D., et al. Genomic amplifications and distal 6q loss: novel markers for poor survival in high-risk neuroblastoma patients. J Natl Cancer Inst. 2018;110(10):1084–1093. PubMed PMC

Lasorsa V.A., Cimmino F., Ognibene M., et al. 19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis. NPJ Genom Med. 2020;5:18. PubMed PMC

Esposito M.R., Binatti A., Pantile M., et al. Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease. Int J Cancer. 2018;143(10):2525–2536. PubMed

Formicola D., Petrosino G., Lasorsa V.A., et al. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma. J Transl Med. 2016;14(1):142. PubMed PMC

Lasorsa V.A., Formicola D., Pignataro P., et al. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Oncotarget. 2016;7(16):21840–21852. PubMed PMC

Tonini G.P., Capasso M. Genetic predisposition and chromosome instability in neuroblastoma. Cancer Metastasis Rev. 2020;39(1):275–285. PubMed

Peifer M., Hertwig F., Roels F., et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526(7575):700–704. PubMed PMC

Capasso M., Lasorsa V.A., Cimmino F., et al. Transcription factors involved in tumorigenesis are over-represented in mutated Active DNA-binding sites in neuroblastoma. Cancer Res. 2020;80(3):382–393. PubMed

Lasorsa V.A., Montella A., Cantalupo S., et al. Somatic mutations enriched in cis-regulatory elements affect genes involved in embryonic development and immune system response in neuroblastoma. Cancer Res. 2022 PubMed

Avitabile M., Lasorsa V.A., Cantalupo S., et al. Association of PARP1 polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma. J Cell Mol Med. 2020;24(7):4072–4081. PubMed PMC

Smith V., Foster J. High-risk neuroblastoma treatment review. Children (Basel) 2018;5(9) PubMed PMC

Kim C., Gao R., Sei E., et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(4):879–893 e813. PubMed PMC

Stewart C.A., Gay C.M., Xi Y., et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1:423–436. PubMed PMC

El-Sayes N., Vito A., Mossman K. Tumor heterogeneity: a great barrier in the age of cancer immunotherapy. Cancers (Basel) 2021;13(4) PubMed PMC

Suva M.L., Tirosh I. Single-cell RNA sequencing in cancer: lessons learned and emerging challenges. Mol Cell. 2019;75(1):7–12. PubMed

Boeva V., Louis-Brennetot C., Peltier A., et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. 2017;49(9):1408–1413. PubMed

van Groningen T., Koster J., Valentijn L.J., et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet. 2017;49(8):1261–1266. PubMed

Jansky S., Sharma A.K., Korber V., et al. Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma. Nat Genet. 2021;53(5):683–693. PubMed

Kameneva P., Artemov A.V., Kastriti M.E., et al. Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin. Nat Genet. 2021;53(5):694–706. PubMed PMC

Kinker G.S., Greenwald A.C., Tal R., et al. Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity. Nat Genet. 2020;52(11):1208–1218. PubMed PMC

Zhang Y., Wang D., Peng M., et al. Single-cell RNA sequencing in cancer research. J Exp Clin Cancer Res. 2021;40(1):81. PubMed PMC

Wang L., Mo S., Li X., He Y., Yang J. Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma. Cancer Biol Med. 2020;17(3):726–739. PubMed PMC

Zheng G.X., Terry J.M., Belgrader P., et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049. PubMed PMC

Stuart T., Butler A., Hoffman P., et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888–1902 e1821. PubMed PMC

Tirosh I., Venteicher A.S., Hebert C., et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 2016;539(7628):309–313. PubMed PMC

Hafemeister C., Satija R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 2019;20(1):296. PubMed PMC

Wickham H. ggplot2. Springers Link. 2016

Newman A.M., Steen C.B., Liu C.L., et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–782. PubMed PMC

Rodrigo M.A.M., Michalkova H., Strmiska V., et al. Metallothionein-3 promotes cisplatin chemoresistance remodelling in neuroblastoma. Sci Rep. 2021;11(1):5496. PubMed PMC

Hientz K., Mohr A., Bhakta-Guha D., Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017;8(5):8921–8946. PubMed PMC

Paul I., Chacko A.D., Stasik I., et al. Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death Dis. 2012;3:e449. PubMed PMC

Yasui K., Mihara S., Zhao C., et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004;64(4):1403–1410. PubMed

Wu C., Yang T., Liu Y., et al. ARNT/HIF-1beta links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. Cancer Med. 2018;7(8):3899–3911. PubMed PMC

Xiao H., Zheng Y., Ma L., Tian L., Sun Q. Clinically-relevant ABC transporter for anti-cancer drug resistance. Front Pharmacol. 2021;12:648407. PubMed PMC

Aissa A.F., Islam A., Ariss M.M., et al. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat Commun. 2021;12(1):1628. PubMed PMC

Park S.R., Namkoong S., Friesen L., et al. Single-cell transcriptome analysis of colon cancer cell response to 5-fluorouracil-induced DNA damage. Cell Rep. 2020;32(8):108077. PubMed PMC

Zhang W., Yu Y., Hertwig F., et al. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biol. 2015;16:133. PubMed PMC

Thirant C, Peltier A, Durand S, et al. Interplay between intrinsic reprogramming potential and microenvironment controls neuroblastoma cell plasticity and identity. 2021:2021.2001.2007.425710.

Gautier M., Thirant C., Delattre O., Janoueix-Lerosey I. Plasticity in neuroblastoma cell identity defines a noradrenergic-to-mesenchymal transition (NMT) Cancers (Basel) 2021;13(12) PubMed PMC

Bahar E., Kim J.Y., Yoon H. Chemotherapy resistance explained through endoplasmic reticulum stress-dependent signaling. Cancers (Basel) 2019;11(3) PubMed PMC

Song H., Liu D., Dong S., et al. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct Target Ther. 2020;5(1):193. PubMed PMC

Cimmino F., Avitabile M., Lasorsa V.A., et al. Functional characterization of full-length BARD1 strengthens its role as a tumor suppressor in neuroblastoma. J Cancer. 2020;11(6):1495–1504. PubMed PMC

Dhillon K.K., Swisher E.M., Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci. 2011;102(4):663–669. PubMed PMC

Penzo M., Montanaro L., Trere D., Derenzini M. The ribosome biogenesis-cancer connection. Cells. 2019;8(1) PubMed PMC

Bruno P.M., Liu Y., Park G.Y., et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017;23(4):461–471. PubMed PMC

Burger K., Muhl B., Harasim T., et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem. 2010;285(16):12416–12425. PubMed PMC

Izzo A., Kamieniarz K., Schneider R. The histone H1 family: specific members, specific functions? Biol Chem. 2008;389(4):333–343. PubMed

Shi C.X., Kortum K.M., Zhu Y.X., et al. CRISPR genome-wide screening identifies dependence on the proteasome subunit PSMC6 for bortezomib sensitivity in multiple myeloma. Mol Cancer Ther. 2017;16(12):2862–2870. PubMed PMC

Shi C.X., Zhu Y.X., Bruins L.A., et al. Proteasome subunits differentially control myeloma cell viability and proteasome inhibitor sensitivity. Mol Cancer Res. 2020;18(10):1453–1464. PubMed PMC

Xuan D.T.M., Wu C.C., Kao T.J., et al. Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients. Aging (Albany NY) 2021;13(22):24882–24913. PubMed PMC

Marengo B., Monti P., Miele M., et al. Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation. Sci Rep. 2018;8(1):13762. PubMed PMC

Rodrigo M.A.M., Buchtelova H., Jimenez A.M.J., et al. Transcriptomic landscape of cisplatin-resistant neuroblastoma cells. Cells. 2019;8(3) PubMed PMC